The problem: Cardiovascular disease is the leading cause of death in the world and costs healthcare systems more to treat than any other disease.
The answer: Biosfer Teslab is applying nuclear magnetic resonance to develop very precise diagnostics. It has developed Liposcale, a test which measures levels of harmful lipoproteins in the blood, as the basis of improved cardiovascular disease risk assessment. The company claims the use of NMR delivers results that are more accurate and precise than current methods.
The company: Biosfer Teslab is a spin-off from Spain’s Rovira i Virgili University and the Pere Virgili Biomedical Research Institute. The Liposcale test is based on research carried out by two doctoral students, Núria Amigó and Roger Mallol, with input from professors Lluís Masana and Xavier Correig.
The company has two patents and has received over €300,000 from investors. It plans to licence the lipoprotein test to universities, research centres, pharmaceutical companies, food companies and clinical analysis laboratories.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
